SCHEMBL21783383

SCHEMBL21783383

Cc1nc(SCc2ccccc2)c(F)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
BRD4 O60885 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
SCN9A Q15858 1/20 0.42
IDO1 P14902 1/20 0.41
SLC29A1 Q99808 1/20 0.41
POLB P06746 2/20 0.40
PPARG P37231 3/20 0.40
P2RX7 Q99572 1/20 0.40
PPARA Q07869 1/20 0.40
TSHR P16473 3/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD9 Q9H8M2 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
NCOA2 Q15596 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046630 1.00 ALDH1A1 (0.44) ALDH1A1TDP1NPSR1MEN1KMT2A
SCHEMBL21773255 0.86 ALDH1A1 (0.48) ALDH1A1TDP1KMT2ASMN1; SMN2PPARG
SCHEMBL21783435 0.85 NPSR1 (0.42) ALDH1A1TDP1NPSR1MEN1KMT2A
SCHEMBL30046068 0.85 NPSR1 (0.42) ALDH1A1TDP1NPSR1MEN1KMT2A
SCHEMBL21783542 0.79 CYP17A1 (0.39) ALDH1A1BRD4BRD9
SCHEMBL24577765 0.78 GCK (0.47) ALDH1A1NPSR1MEN1KMT2ABRD4
SCHEMBL29759851 0.78 GCK (0.47) ALDH1A1NPSR1MEN1KMT2ABRD4
SCHEMBL31120650 0.78 NPSR1 (0.45) ALDH1A1NPSR1MEN1KMT2ABRD4
SCHEMBL1820035 0.75 NPSR1 (0.43) ALDH1A1NPSR1MEN1KMT2ABRD4
SCHEMBL21783488 0.75 LCK (0.36) BRD4BRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN disclosed
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 CN disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS SCN1A, SCN2A, SCN2B ALDH1A1 3021/4885TDP1 2796/4885NPSR1 471/4885
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885NPSR1 455/4885
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors SCN1A, SCN2A, SCN2B ALDH1A1 3021/4885TDP1 2796/4885NPSR1 471/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885NPSR1 455/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885NPSR1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.